Natasha Giordano - Adicet Bio Director
| ACET Stock | USD 1.88 0.00 0.00% |
Director
Ms. Natasha Giordano is Director of Aceto Corporationration She was the President and Chief Executive Officer as well as a Director of PLx Pharma Inc. since January 2016. PLx Pharma is a latestage specialty pharmaceutical company focused on developing a clinically validated and patent protected delivery system to provide safer and more effective aspirin products. Previously, Ms. Giordano served as the Chief Executive Officer of ClearPoint Learning, Inc., from May 2015 through November 2015 and a director of ClearPoint from December 2009 through November 2015. Prior to ClearPoint, Ms. Giordano served as the Chief Executive Officer of Healthcare Corporation of America through August 2014. From 2009 to August 2012, Ms. Giordano served as Chief Operating Officer and then Chief Executive Officer and President of Xanodyne Pharmaceuticals, Inc., a branded specialty pharmaceutical company. From 2000 to 2008, she served in various senior management positions at Cegedim Dendrite, including serving as President, Americas from 2007 to 2008. Earlier in her career, Ms. Giordano worked for nine years at ParkeDavis, a subsidiary of Warner Lambert since 2010.
| Age | 55 |
| Tenure | 14 years |
| Address | 131 Dartmouth Street, Boston, MA, United States, 02116 |
| Phone | 650 503 9095 |
| Web | https://www.adicetbio.com |
Adicet Bio Management Efficiency
The company has return on total asset (ROA) of (0.308) % which means that it has lost $0.308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6169) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.67 in 2024. Liabilities And Stockholders Equity is likely to gain to about 214.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 18.3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Scadden | Agios Pharm | 65 | |
| Marc TessierLavigne | Agios Pharm | 55 | |
| Carl Gordon | Alector | 53 | |
| Louis Lavigne | Alector | 69 | |
| Doug Cole | Agios Pharm | 54 | |
| Douglas Cole | Agios Pharm | 54 | |
| John Maraganore | Agios Pharm | 55 | |
| Terry McGuire | Alector | 61 | |
| Ian Clark | Agios Pharm | 57 | |
| Maykin Ho | Agios Pharm | 65 | |
| Kendra Adams | Agios Pharm | N/A | |
| Jacqualyn Fouse | Agios Pharm | 56 | |
| Perry Karsen | Agios Pharm | 59 | |
| David Wehner | Alector | 49 | |
| Robert Nelsen | Agios Pharm | 51 | |
| Paul Clancy | Agios Pharm | 56 | |
| Lewis Cantley | Agios Pharm | 75 | |
| Kristine Yaffe | Alector | N/A | |
| Richard Scheller | Alector | 65 | |
| Kaye FosterCheek | Agios Pharm | 58 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.31 |
Adicet Bio Leadership Team
Elected by the shareholders, the Adicet Bio's board of directors comprises two types of representatives: Adicet Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adicet. The board's role is to monitor Adicet Bio's management team and ensure that shareholders' interests are well served. Adicet Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adicet Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesco MD, Chief VP | ||
| Edward Borkowski, CFO | ||
| Rebecca Roof, Interim CFO | ||
| Hans Noetzli, Lead Independent Director | ||
| Douglas Roth, CFO, Principal Accounting Officer, Chief Admin. Officer, Sr. VP, Treasurer and Assistant Secretary | ||
| Natasha Giordano, Director | ||
| Alan Levin, Independent Director | ||
| Daniel Yarosh, Director | ||
| Salvatore Guccione, CEO and President and Director | ||
| Albert Eilender, Chairman of the Board | ||
| BA CPA, Pres CEO | ||
| Jody Burfening, IR Contact Officer | ||
| Blake Aftab, Senior Officer | ||
| William Britton, Independent Director | ||
| Terry Kippley, Senior Vice President - Agricultural Protection Products | ||
| Amy Locke, Head Resources | ||
| Frances Scally, Chief Accounting Officer | ||
| Satish Srinivasan, President and COO of Rising Pharmaceuticals | ||
| Frank DeBenedittis, Sr. VP of Corporate Bus. Devel. and International Sr. VP of Active Pharmaceutical Ingredients | ||
| Donald Healey, Chief Officer | ||
| Richard Randall, Independent Director | ||
| Brian Harvey, Chief Officer | ||
| Carlos Restrepo, Senior Vice President - Performance Chemicals | ||
| Vimal Kavuru, President of Rising | ||
| Nicholas Shackley, Senior Vice President - Pharmaceutical Ingredients | ||
| Steven Rogers, Sr. VP, General Counsel and Corporate Secretary | ||
| Walter Kaczmarek, COO | ||
| William Kennally, Director | ||
| Charles Alaimo, Senior Vice President - Human Resources | ||
| Fran Scally, Chief Accounting Officer | ||
| Raymond Bartone, Senior Vice President - Nutritionals | ||
| Aya Jakobovits, Founder Director |
Adicet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adicet Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 25.52 M | ||||
| Shares Outstanding | 82.15 M | ||||
| Shares Owned By Insiders | 1.42 % | ||||
| Shares Owned By Institutions | 68.02 % | ||||
| Number Of Shares Shorted | 7.69 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 9.72 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adicet Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adicet Bio's short interest history, or implied volatility extrapolated from Adicet Bio options trading.
Pair Trading with Adicet Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adicet Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adicet Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Adicet Stock
| 0.76 | DD | Dupont De Nemours Earnings Call This Week | PairCorr |
| 0.7 | MMM | 3M Company Earnings Call This Week | PairCorr |
| 0.7 | BAC | Bank of America Sell-off Trend | PairCorr |
| 0.69 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.68 | XOM | Exxon Mobil Corp Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Adicet Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adicet Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adicet Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adicet Bio to buy it.
The correlation of Adicet Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adicet Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adicet Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adicet Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adicet Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.Note that the Adicet Bio information on this page should be used as a complementary analysis to other Adicet Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Adicet Stock analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Adicet Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adicet Bio. If investors know Adicet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adicet Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.62) |
The market value of Adicet Bio is measured differently than its book value, which is the value of Adicet that is recorded on the company's balance sheet. Investors also form their own opinion of Adicet Bio's value that differs from its market value or its book value, called intrinsic value, which is Adicet Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adicet Bio's market value can be influenced by many factors that don't directly affect Adicet Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adicet Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adicet Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adicet Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.